Our study provides an important new insight into how pharmacological blockade of RAS (a well-established strategy in the management of hypertension and other cardiovascular diseases) relates to ACE2 expression and its contemplated role in COVID-19-driven organ injury. Here, ACE2 is linked to COVID-19.